- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01123915
A Safety and Immunogenicity Study of 3 Doses of Opal Immunotherapy in HIV Infected People
A Phase 1, Dose Escalating, Single Centre, Double Blind Study of the Safety and Immunogenicity of Opal-HIV-Gag Clade C in HIV Positive Subjects
This phase I study is the first step to determine if Opal immunotherapy may have potential utility as a treatment for HIV. Although effective treatments for HIV infection exist, they are limited by the requirement for life-long daily treatment, cost, side effects, and the development of resistance.
There is a need for therapeutic approaches that induce or enhance T-cell immunity to control HIV disease. Overlapping Peptide-pulsed Autologous Cells (Opal) is a technique where autologous peripheral blood mononuclear cells (PBMC) or whole blood is pulsed with sets of overlapping peptides spanning whole proteins of HIV.
Study Overview
Status
Conditions
Detailed Description
Opal-HIV-Gag(c) is not for direct injection and is administered by ex vivo incubation of whole blood or separated blood components (such as white blood cells or peripheral blood mononuclear cells) and reinfusion.
As a practical alternative to PBMC separation and to optimise vaccine presentation during the ex vivo incubation, a blood cell separation device will be used to separate the whole blood and enrich the white blood cell component. The device processes whole blood in a closed, single use disposable kit. Reconstituted Opal-HIV-Gag(c)or matching placebo will be added to the white blood cells, incubated for one hour and reinfused into the subject. Subjects will receive 4 administrations at 4 weekly intervals. Subjects are followed for 12 weeks after the final administration.
Each dose group will be enrolled sequentially, with a sentinel group for each dose group. Satisfactory safety data from each cohort, reviewed by a Data Safety Monitoring Board, will permit dose escalation.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom, SW10 9NH
- St Stephen's Centre, Chelsea and Westminster Foundation Trust
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Provision of written informed consent
- Documented laboratory diagnosis of HIV 1 infection
- Documented HIV clade of infection
- 18 - 60 years of age, inclusive
- Stable antiretroviral therapy (ART) regimen containing at least 3 active ART agents for at least 2 months prior to Baseline
- Plasma HIV-Ribonucelc acid (RNA) <400 copies/millilitre (mL) for 6 months up to and including Screening. Subjects on stable ART with a single value ≥400 copies/mL (i.e. the result is unconfirmed by subsequent testing) within this timeframe may be included at the discretion of the Investigator
- CD4+ T-cell count ≥350 cells/cubic millimetres (mm3) at Screening (with nadir ≥100 cells/mm3)
- A positive immunogenic response when stimulated with HIV-1 Gag clade C peptides at Screening
- Male or female. Women of child-bearing potential must be using two effective methods of contraception and agree to continue to do so from Screening, throughout study medication dosing and for 28 days after the last dose of study medication
Exclusion Criteria:
- Any serious or active medical or psychiatric illness which, in the opinion of the Investigator, would interfere with treatment, assessment, compliance with the protocol, or subject safety. This would include any active clinically significant renal, cardiac, pulmonary, vascular, or metabolic (thyroid disorders, adrenal disease) illness, or malignancy
- Hepatitis B virus surface antigen, or Hepatitis C virus (HCV) antibody and HCV-RNA positive at Screening
- Female subjects who are lactating and those of reproductive potential with a positive urine pregnancy test at either Screening or Baseline
- A new AIDS-defining condition diagnosed within 42 days prior to Baseline visit
- Known or suspected allergy to Dimethyl Sulfoxide
- History of allergy or reaction to medications (including peptide or protein containing agents) or history of severe allergy that, in the opinion of the Investigator, might compromise the subject's participation in any way
- Moderate or severe asthma, defined as at least chronic moderate symptoms which frequently interfere with daily activities and require anti-asthma/anti-inflammatory agents
- Have received immunomodulating agents (including immunosuppressive agents, interferon or other immune or cytokine-based therapies), immunisation, and/or systemic chemotherapeutic agents within 60 days of Screening or expected to receive these agents during the course of the study
- Recipient of live attenuated vaccines within 60 days of Screening
- Recipient of whole killed, toxoid or sub-unit vaccines (e.g. influenza, pneumococcus, tetanus, hepatitis B) within 42 days prior to Baseline
- Ever received an HIV prophylactic or immunotherapeutic vaccine (does not apply to subjects who have written documentation of receiving placebo or adjuvant only)
- Recreational and/or therapeutic drug or alcohol use that, in the opinion of the Investigator, might compromise the subject's participation in any way.
- Medical or psychiatric condition or occupational responsibilities that may preclude compliance with the protocol
Laboratory blood values:
- Haemoglobin <11.0 grams/decilitre (g/dL) for men and <10.0 g/dL for women
- Neutrophil count <800/mm3
- Platelet count <50,000/mm3
- Aspartate aminotransferase or Alanine transaminase >2.5 times Upper Limit of Normal (ULN)
- Lipase >2.5 times ULN
- Amylase >1.5 times ULN (unless serum lipase is ≤1.5 times ULN)
- Subjects with an estimated creatinine clearance of <80 mL/minute
- Recipients of blood products or immunoglobulins within 6 months prior to Screening or loss of 450 mL or more of blood during the three months prior to Screening
- Recipients of experimental or investigational agents within 30 days prior to Screening
- Previous participation in this study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Opal-HIV-Gag(c)
Opal-HIV-Gag(c) administered ex vivo to separated white blood cells on 4 occasions at 4 weekly intervals.
|
|
PLACEBO_COMPARATOR: Diluent
Administered ex vivo to separated white blood cells on 4 occasions at 4 weekly intervals.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety
Time Frame: Several points throughout the 12 week active phase and 12 week and follow up period
|
Examined through treatment-emergent adverse events, vital signs and routine laboratory screening.
|
Several points throughout the 12 week active phase and 12 week and follow up period
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Immunogenicity
Time Frame: Several points throughout the 12 week active phase and 12 week and follow up period
|
Immunogenicity will be assessed by ELISpot and other markers of immune response
|
Several points throughout the 12 week active phase and 12 week and follow up period
|
Impact on HIV infection
Time Frame: Several points throughout the 12 week active phase and 12 week and follow up period
|
Assessed by HIV-1 viral load and CD4 T-cell counts.
|
Several points throughout the 12 week active phase and 12 week and follow up period
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Kloverpris HN, Jackson A, Handley A, Hayes P, Gilmour J, Riddell L, Chen F, Atkins M, Boffito M, Walker BD, Ackland J, Sullivan M, Goulder P. Non-immunogenicity of overlapping gag peptides pulsed on autologous cells after vaccination of HIV infected individuals. PLoS One. 2013 Oct 4;8(10):e74389. doi: 10.1371/journal.pone.0074389. eCollection 2013.
- Jackson A, Kloverpris HN, Boffito M, Handley A, Atkins M, Hayes P, Gilmour J, Riddel L, Chen F, Bailey-Tippets M, Walker B, Ackland J, Sullivan M, Goulder P. A randomised, placebo-controlled, first-in-human study of a novel clade C therapeutic peptide vaccine administered ex vivo to autologous white blood cells in HIV infected individuals. PLoS One. 2013 Sep 17;8(9):e73765. doi: 10.1371/journal.pone.0073765. eCollection 2013.
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- HIV Infections
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Protective Agents
- Antioxidants
- Free Radical Scavengers
- Cryoprotective Agents
- Dimethyl Sulfoxide
Other Study ID Numbers
- Opal-HIV-1001
- 2008-005142-23 (EUDRACT_NUMBER)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on Opal-HIV-Gag(c) Low Dose
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCTerminated
-
Kolon Life ScienceCompletedDegenerative ArthritisKorea, Republic of
-
Kolon Life ScienceCompletedDegenerative ArthritisKorea, Republic of
-
Kolon TissueGene, Inc.Not yet recruiting
-
Kolon Life ScienceCompletedDegenerative ArthritisKorea, Republic of
-
Merck Sharp & Dohme LLCHIV Vaccine Trials NetworkTerminatedHIV Infections | AIDS
-
Affiliated Hospital of Guangdong Medical UniversityNot yet recruiting
-
Gilead SciencesActive, not recruitingHIV Infections | Acquired Immune Deficiency Syndrome (AIDS)United States, Thailand, Uganda, South Africa, Zimbabwe